Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
type: MedicalStudy
description: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer: an Open-label, Multicenter, Single Arm Phase 2 Study
status: RECRUITING
study design: INTERVENTIONAL
phase: PHASE2
start date: 2024-02-28
end date: 2029-12-30
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT06055465
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Chinese University of Hong Kong
study subject: Lung Cancer
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: RECRUITING
keywords: Lung Cancer

AI Analytics
type: Organization